Schedule of investments
Delaware Healthcare Fund December 31, 2019 (Unaudited)
Number of shares | Value (US $) | ||
Common Stock – 100.50% ✧ | |||
Biotechnology - 36.26% | |||
ACADIA Pharmaceuticals † | 194,776 | $ | 8,332,517 |
Alder Biopharmaceuticals =† | 75,000 | 66,000 | |
Alexion Pharmaceuticals † | 20,000 | 2,163,000 | |
Alkermes † | 370,000 | 7,548,000 | |
Allogene Therapeutics † | 146,779 | 3,813,318 | |
Alnylam Pharmaceuticals † | 41,000 | 4,721,970 | |
Arena Pharmaceuticals † | 525,000 | 23,845,500 | |
ArQule † | 630,000 | 12,574,800 | |
Audentes Therapeutics † | 153,941 | 9,211,829 | |
Axovant Gene Therapies † | 64,171 | 328,556 | |
BioMarin Pharmaceutical † | 112,000 | 9,469,600 | |
Cellectis ADR † | 219,675 | 3,760,836 | |
Clovis Oncology † | 100,200 | 1,044,585 | |
Coherus Biosciences † | 430,000 | 7,742,150 | |
Dynavax Technologies † | 760,000 | 4,347,200 | |
Epizyme † | 203,200 | 4,998,720 | |
Exact Sciences † | 17,116 | 1,582,919 | |
Five Prime Therapeutics † | 100,000 | 459,000 | |
Fortress Biotech † | 100,000 | 257,000 | |
Galmed Pharmaceuticals † | 306,010 | 1,768,738 | |
Immunomedics † | 445,000 | 9,416,200 | |
Incyte † | 60,000 | 5,239,200 | |
Intercept Pharmaceuticals † | 27,000 | 3,345,840 | |
Karyopharm Therapeutics † | 380,000 | 7,284,600 | |
Lexicon Pharmaceuticals † | 11,697 | 48,543 | |
MacroGenics † | 275,000 | 2,992,000 | |
Madrigal Pharmaceuticals † | 28,500 | 2,596,635 | |
MEI Pharma † | 600,000 | 1,488,000 | |
Mirati Therapeutics † | 165,000 | 21,261,900 | |
Momenta Pharmaceuticals † | 141,501 | 2,791,815 | |
MorphoSys † | 339,685 | 48,052,076 | |
Mustang Bio † | 120,000 | 489,600 | |
Myriad Genetics † | 135,000 | 3,676,050 | |
Nektar Therapeutics † | 165,000 | 3,561,525 | |
Neurocrine Biosciences † | 110,000 | 11,823,900 | |
NextCure † | 100,000 | 5,633,000 | |
Portola Pharmaceuticals † | 130,000 | 3,104,400 | |
Proteostasis Therapeutics † | 750,000 | 1,710,000 | |
Provention Bio † | 70,000 | 1,043,000 | |
Puma Biotechnology † | 61,255 | 535,981 | |
Regeneron Pharmaceuticals † | 101,000 | 37,923,480 |
NQ-573 [12/19] 2/20 (1081398) 1
Schedule of investments
Delaware Healthcare Fund (Unaudited)
Number of shares | Value (US $) | ||
Common Stock ✧ (continued) | |||
Biotechnology(continued) | |||
REGENXBIO † | 149,000 | $ | 6,104,530 |
Rigel Pharmaceuticals † | 1,600,000 | 3,424,000 | |
Rocket Pharmaceuticals † | 58,000 | 1,320,080 | |
Sangamo Therapeutics † | 400,000 | 3,348,000 | |
Sarepta Therapeutics † | 23,000 | 2,967,920 | |
Seattle Genetics † | 95,000 | 10,854,700 | |
Syndax Pharmaceuticals † | 180,000 | 1,580,400 | |
Ultragenyx Pharmaceutical † | 70,000 | 2,989,700 | |
uniQure † | 696,000 | 49,875,360 | |
United Therapeutics † | 86,800 | 7,645,344 | |
Vascular Biogenics † | 200,000 | 240,000 | |
Vertex Pharmaceuticals † | 25,000 | 5,473,750 | |
Viking Therapeutics † | 330,100 | 2,647,402 | |
Voyager Therapeutics † | 5,700 | 79,515 | |
Xencor † | 129,191 | 4,442,878 | |
XOMA † | 3,466 | 94,622 | |
385,142,184 | |||
Blue Chip Medical Products - 42.31% | |||
AbbVie | 130,000 | 11,510,200 | |
Amgen | 246,964 | 59,535,611 | |
AstraZeneca | 110,000 | 11,083,855 | |
AstraZeneca ADR | 60,000 | 2,991,600 | |
Biogen † | 45,000 | 13,352,850 | |
Boston Scientific † | 380,000 | 17,183,600 | |
Bristol-Myers Squibb | 200,000 | 12,838,000 | |
Chugai Pharmaceutical | 330,000 | 30,391,433 | |
Eli Lilly & Co. | 181,446 | 23,847,448 | |
Gilead Sciences | 240,000 | 15,595,200 | |
GlaxoSmithKline ADR | 280,000 | 13,157,200 | |
Johnson & Johnson | 100,000 | 14,587,000 | |
Merck & Co. | 155,000 | 14,097,250 | |
Pfizer | 500,000 | 19,590,000 | |
Roche Holding | 180,000 | 58,500,507 | |
Sanofi | 380,000 | 38,200,167 | |
Sanofi ADR | 1,350,000 | 67,770,000 | |
Stryker | 15,000 | 3,149,100 | |
Teva Pharmaceutical Industries ADR † | 530,000 | 5,194,000 | |
UCB | 60,000 | 4,771,712 | |
Zimmer Biomet Holdings | 80,000 | 11,974,400 | |
449,321,133 |
2 NQ-573 [12/19] 2/20 (1081398)
(Unaudited)
Number of shares | Value (US $) | ||
Common Stock ✧ (continued) | |||
Healthcare Services - 10.40% | |||
Anthem | 50,000 | $ | 15,101,500 |
Cigna | 75,000 | 15,336,750 | |
CVS Health | 345,000 | 25,630,050 | |
DaVita † | 60,000 | 4,501,800 | |
McKesson | 15,100 | 2,088,632 | |
Quest Diagnostics | 48,000 | 5,125,920 | |
UnitedHealth Group | 120,000 | 35,277,600 | |
Walgreens Boots Alliance | 125,000 | 7,370,000 | |
110,432,252 | |||
Other - 4.76% | |||
Cia de Minas Buenaventura ADR | 115,300 | 1,741,030 | |
Dell Technologies Class C † | 102,600 | 5,272,614 | |
Fannie Mae † | 1,300,000 | 4,056,000 | |
Federal Home Loan Mortgage † | 1,050,000 | 3,153,990 | |
Micron Technology † | 436,600 | 23,480,348 | |
Opera ADR † | 184,700 | 1,708,475 | |
QUALCOMM | 50,000 | 4,411,500 | |
SINA † | 60,000 | 2,395,800 | |
Sohu. com ADR † | 390,722 | 4,368,272 | |
50,588,029 | |||
Small- / Mid-Cap Medical Products - 6.77% | |||
ABIOMED † | 30,000 | 5,117,700 | |
Aerie Pharmaceuticals † | 5,100 | 123,267 | |
Akorn † | 501,000 | 751,500 | |
Allergan | 111,500 | 21,315,455 | |
Dermira † | 150,000 | 2,274,000 | |
Halozyme Therapeutics † | 230,000 | 4,077,900 | |
Inspire Medical Systems † | 30,000 | 2,226,300 | |
Intra-Cellular Therapies † | 100,000 | 3,431,000 | |
Mylan † | 1,080,000 | 21,708,000 | |
Perrigo | 210,000 | 10,848,600 | |
71,873,722 | |||
Total Common Stock(cost $810,369,011) | 1,067,357,320 | ||
Rights – 0.02% | |||
Ambit Bioscience =† | 76,500 | 0 | |
Bristol-Myers Squibb † | 80,000 | 240,800 | |
Total Right(cost $0) | 240,800 |
NQ-573 [12/19] 2/20 (1081398) 3
Schedule of investments
Delaware Healthcare Fund (Unaudited)
Total Value of Securities – 100.52% | |||
(cost $810,369,011) | $ | 1,067,598,120 | |
Liabilities Net of Receivables and Other Assets – (0.52%) | (5,480,675) | ||
Net Assets Applicable to 40,086,410 Shares Outstanding – 100.00% | $ | 1,062,117,445 |
✧ | Narrow industries are utilized for compliance purposes for diversification whereas broad sectors are |
used for financial reporting. | |
= | The value of this security was determined using significant unobservable inputs and is reported as a |
Level 3 security. | |
† | Non-income producing security. |
ADR – American Depositary Receipt |
4 NQ-573 [12/19] 2/20 (1081398)